Cardiovascular Complications of Obesity and the Metabolic Syndrome

  • Paul Poirier
  • Robert H. Eckel


  • At any given level of effort, the cardiac workload is greater in obese subjects.

  • Left ventricular hypertrophy occurs with morbid obesity and may be associated with left ventricular diastolic dysfunction.

  • With increasing rates of obesity, type 2 diabetes and the metabolic syndrome are seen in childhood.

  • The metabolic syndrome and inflammation are associated.

  • Genetic factors play an important role in obesity.

  • Obesity is strongly associated with systemic arterial hypertension.

  • There is an increased stroke risk with obesity.

  • Obesity is strongly associated with systemic arterial hypertension.

  • Morbid obesity is an independent risk factor for death after pulmonary embolism.

  • Obesity is a classical cause of alveolar hypoventilation.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Eckel RH, York DA, Rossner S, et al. Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: executive summary. Circulation 2004;110:2968–2975.PubMedGoogle Scholar
  2. 2.
    World Health Organization. Obesity: preventing and managing the global epidemic. WHO Technical report series 894. Geneva: World Health Organization, 2000.Google Scholar
  3. 3.
    Engeland A, Bjorge T, Sogaard AJ, et al. Body mass index in adolescence in relation to total mortality: 32-year follow-up of 227,000 Norwegian boys and girls. Am J Epidemiol 2003;157:517–523.PubMedGoogle Scholar
  4. 4.
    Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002;288:1723–1727.PubMedGoogle Scholar
  5. 5.
    Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United States: prevalence and trends, 1960–1994. Int J Obes Relat Metab Disord 1998;22:39–47.PubMedGoogle Scholar
  6. 6.
    Poirier P, Eckel RH. Obesity and cardiovascular disease. Curr Atheroscler Rep 2002;4:448–453.PubMedGoogle Scholar
  7. 7.
    Poirier P, Eckel RH. The heart and obesity. In: Fuster V, Alexander RW, King S, O’Rourke RA, Roberts R, Wellens HJJ, eds. Hurst’s The Heart. New York: McGraw-Hill, 2000:2289–2303.Google Scholar
  8. 8.
    Ogden CL, Flegal KM, Carroll MD, et al. Prevalence and trends in overweight among US children and adolescents, 1999–2000. JAMA 2002;288:1728–1732.PubMedGoogle Scholar
  9. 9.
    Teixeira PJ, Sardinha LB, Going SB, et al. Total and regional fat and serum cardiovascular disease risk factors in lean and obese children and adolescents. Obes Res 2001;9:432–442.PubMedGoogle Scholar
  10. 10.
    Must A, Jacques PF, Dallal GE, et al. Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med 1992;327:1350–1355.PubMedGoogle Scholar
  11. 11.
    Lawlor DA, Leon DA. Association of body mass index and obesity measured in early childhood with risk of coronary heart disease and stroke in middle age: findings from the Aberdeen children of the 1950s prospective cohort study. Circulation 2005;111:1891–1896.PubMedGoogle Scholar
  12. 12.
    Flegal KM, Graubard BI, Williamson DF, et al. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005;293:1861–1867.PubMedGoogle Scholar
  13. 13.
    Wilson PW, D’Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002;162:1867–1872.PubMedGoogle Scholar
  14. 14.
    Drenick EJ, Bale GS, Seltzer F, et al. Excessive mortality and causes of death in morbidly obese men. JAMA 1980;243:443–445.PubMedGoogle Scholar
  15. 15.
    Fontaine KR, Redden DT, Wang C, et al. Years of life lost due to obesity. JAMA 2003;289:187–193.PubMedGoogle Scholar
  16. 16.
    Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med 2003;138:24–32.PubMedGoogle Scholar
  17. 17.
    Hu FB, Willett WC, Li T, et al. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med 2004;351:2694–2703.PubMedGoogle Scholar
  18. 18.
    Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the Interheart study): case-control study. Lancet 2004;364:937–952.PubMedGoogle Scholar
  19. 19.
    Yusuf S, Vaz M, Pais P. Tackling the challenge of cardiovascular disease burden in developing countries. Am Heart J 2004;148:1–4.PubMedGoogle Scholar
  20. 20.
    National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report. Obes Res 1998;suppl 2:51S–209S.Google Scholar
  21. 21.
    Kuczmarski RJ, Flegal KM, Campbell SM, et al. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994;272:205–211.PubMedGoogle Scholar
  22. 22.
    Mokdad AH, Serdula MK, Dietz WH, et al. The spread of the obesity epidemic in the United States, 1991–1998. JAMA 1999;282:1519–1522.PubMedGoogle Scholar
  23. 23.
    Eckel RH. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1997;96:3248–3250.PubMedGoogle Scholar
  24. 24.
    Eckel RH, Krauss RM. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 1998;97:2099–2100.PubMedGoogle Scholar
  25. 25.
    Christian HA. Some newer aspects of the pathology of fat and fatty infiltration. Bull Johns Hopkins Hosp 1905;16:1–6.Google Scholar
  26. 26.
    Crandall DL, Hausman GJ, Kral JG. A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives. Microcirculation 1997;4:211–232.PubMedGoogle Scholar
  27. 27.
    Rosell S, Belfrage E. Blood circulation in adipose tissue. Physiol Rev 1979;59:1078–1104.PubMedGoogle Scholar
  28. 28.
    Larsen OA, Lassen NA, Quaade F. Blood flow through human adipose tissue determined with radioactive xenon. Acta Physiol Scand 1966;66:337–345.PubMedGoogle Scholar
  29. 29.
    Lesser GT, Deutsch S. Measurement of adipose tissue blood flow and perfusion in man by uptake of 85 Kr. J Appl Physiol 1967;23:621–630.PubMedGoogle Scholar
  30. 30.
    Oberg B, Rosell S. Sympathetic control of consecutive vascular sections in canine subcutaneous adipose tissue. Acta Physiol Scand 1967;71:47–56.PubMedGoogle Scholar
  31. 31.
    Karpe F, Fielding BA, Ilic V, et al. Monitoring adipose tissue blood flow in man: a comparison between the (133)xenon washout method and microdialysis. Int J Obes Relat Metab Disord 2002;26:1–5.PubMedGoogle Scholar
  32. 32.
    Karpe F, Fielding BA, Ilic V, et al. Impaired postprandial adipose tissue blood flow response is related to aspects of insulin sensitivity. Diabetes 2002;51:2467–2473.PubMedGoogle Scholar
  33. 33.
    Summers LK, Samra JS, Humphreys SM, et al. Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. Clin Sci (Lond) 1996;91:679–683.PubMedGoogle Scholar
  34. 34.
    Linde B, Chisolm G. The interstitial space of adipose tissue as determined by single injection and equilibration techniques. Acta Physiol Scand 1975;95:383–390.PubMedGoogle Scholar
  35. 35.
    Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995;95:2111–2119.PubMedGoogle Scholar
  36. 36.
    Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409–2415.PubMedGoogle Scholar
  37. 37.
    Lundgren CH, Brown SL, Nordt TK, et al. Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996;93:106–110.PubMedGoogle Scholar
  38. 38.
    Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307–312.PubMedGoogle Scholar
  39. 39.
    Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000;21:697–738.PubMedGoogle Scholar
  40. 40.
    Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005;146:1764–1771.PubMedGoogle Scholar
  41. 41.
    Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426–430.PubMedGoogle Scholar
  42. 42.
    Yudkin JS, Stehouwer CD, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972–978.PubMedGoogle Scholar
  43. 43.
    Cigolini M, Targher G, Bergamo AI, et al. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 1996;16:368–374.PubMedGoogle Scholar
  44. 44.
    Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997;82:4196–4200.PubMedGoogle Scholar
  45. 45.
    Ridker PM. Novel risk factors and markers for coronary disease. Adv Intern Med 2000;45:391–418.PubMedGoogle Scholar
  46. 46.
    Alpert MA. Obesity cardiomyopathy; pathophysiology and evolution of the clinical syndrome. Am J Med Sci 2001;321:225–236.PubMedGoogle Scholar
  47. 47.
    Kasper EK, Hruban RH, Baughman KL. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. Am J Cardiol 1992;70:921–924.PubMedGoogle Scholar
  48. 48.
    Mattsson E, Larsson UE, Rossner S. Is walking for exercise too exhausting for obese women? Int J Obes Relat Metab Disord 1997;21:380–386.PubMedGoogle Scholar
  49. 49.
    Poirier P, Despres JP. Exercise in weight management of obesity. Cardiol Clin 2001;19:459–470.PubMedGoogle Scholar
  50. 50.
    Kaltman AJ, Goldring RM. Role of circulatory congestion in the cardiorespiratory failure of obesity. Am J Med 1976;60:645–653.PubMedGoogle Scholar
  51. 51.
    Messerli FH, Nunez BD, Ventura HO, et al. Overweight and sudden death. Increased ventricular ectopy in cardiopathy of obesity. Arch Intern Med 1987;147:1725–1728.PubMedGoogle Scholar
  52. 52.
    Messerli FH. Cardiopathy of obesity—a not-so-Victorian disease. N Engl J Med 1986;314:378–380.PubMedGoogle Scholar
  53. 53.
    Ku CS, Lin SL, Wang DJ, et al. Left ventricular filling in young normotensive obese adults. Am J Cardiol 1994;73:613–615.PubMedGoogle Scholar
  54. 54.
    Sasson Z, Rasooly Y, Gupta R, et al. Left atrial enlargement in healthy obese: prevalence and relation to left ventricular mass and diastolic function. Can J Cardiol 1996;12:257–263.PubMedGoogle Scholar
  55. 55.
    Wang TJ, Parise H, Levy D, et al. Obesity and the risk of newonset atrial fibrillation. JAMA 2004;292:2471–2477.PubMedGoogle Scholar
  56. 56.
    Backman L, Freyschuss U, Hallberg D, et al. Reversibility of cardiovascular changes in extreme obesity. Effects of weight reduction through jejunoileostomy. Acta Med Scand 1979;205:367–373.PubMedGoogle Scholar
  57. 57.
    Alexander JK, Peterson KL. Cardiovascular effects of weight reduction. Circulation 1972;45:310–318.PubMedGoogle Scholar
  58. 58.
    Cheyne J. A case of apoplexy in which the fleshy part of the heart was converted into fat. Dublin Hosp Rep 1818;2:216–223.Google Scholar
  59. 59.
    Carpenter CL. Myocardial fat infiltration. Am Heart J 1962;63:491–496.PubMedGoogle Scholar
  60. 60.
    Smith HL, Willius FA. Adiposity of the heart: a clinical and pathologic study of one hundred and thirty-six obese patients. Arch Intern Med 1933;52:911–931.Google Scholar
  61. 61.
    Amad KH, Brennan JC, Alexander JK. The cardiac pathology of chronic exogenous obesity. Circulation 1965;32:740–745.PubMedGoogle Scholar
  62. 62.
    Saphir O, Corrigan M. Fatty infiltration of the myocardium. Arch Intern Med 1933;52:410–428.Google Scholar
  63. 63.
    Master AM, Oppenheimer ET. A study of obesity: circulatory, roentgen-ray and electrocardiographic investigations. JAMA 1929;92:1652–1656.Google Scholar
  64. 64.
    Quain R. Fatty diseases of the heart. Med Chirurg Trans 1850;33:121–196.Google Scholar
  65. 65.
    House AA, Walley VM. Right heart failure due to ventricular adiposity: ‘adipositas cordis’—an old diagnosis revisited. Can J Cardiol 1996;12:485–489.PubMedGoogle Scholar
  66. 66.
    Pratt JH. On the causes of cardiac insufficiency. Bull Johns Hopkins Hosp 1904;15:301–309.Google Scholar
  67. 67.
    Master AM. Fatty degeneration of the heart. Arch Intern Med 1923;22:221–231.Google Scholar
  68. 68.
    Alpert MA, Lambert CR, Terry BE, et al. Effect of weight loss on left ventricular mass in nonhypertensive morbidly obese patients. Am J Cardiol 1994;73:918–921.PubMedGoogle Scholar
  69. 69.
    Alpert MA, Kelly DL. Value and limitations of echocardiography assessment of obese patients. Echocardiography 1986;3:261–272.Google Scholar
  70. 70.
    Ansari A, Rholl AO. Pseudopericardial effusion: echocardiographic and computed tomographic correlations. Clin Cardiol 1986;9:551–555.PubMedGoogle Scholar
  71. 71.
    Savage DD, Garrison RJ, Brand F, et al. Prevalence and correlates of posterior extra echocardiographic spaces in a free-living population based sample (the Framingham study). Am J Cardiol 1983;51:1207–1212.PubMedGoogle Scholar
  72. 72.
    Prior JT. Lipomatous hypertrophy of the cardiac interatrial septum. A lesion resembling hibernoma, lipoblastomatosis and infiltrating lipoma. Arch Pathol 1964;78:11.PubMedGoogle Scholar
  73. 73.
    Page DL. Lipomatous hypertrophy of the cardiac interatrial septum: its development and probable clinical significance. Hum Pathol 1970;1:151–163.PubMedGoogle Scholar
  74. 74.
    Alpert MA, Lambert CR, Panayiotou H, et al. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am J Cardiol 1995;76:1194–1197.PubMedGoogle Scholar
  75. 75.
    Karason K, Lindroos AK, Stenlof K, et al. Relief of cardiorespiratory symptoms and increased physical activity after surgically induced weight loss. Results from the Swedish Obese Subjects Study. Arch Intern Med 2000;160:1797–1802.PubMedGoogle Scholar
  76. 76.
    Alpert MA, Lambert CR, Terry BE, et al. Effect of weight loss on left ventricular diastolic filling in morbid obesity. Am J Cardiol 1995;76:1198–1201.PubMedGoogle Scholar
  77. 77.
    Chakko S, Mayor M, Allison MD, et al. Abnormal left ventricular diastolic filling in eccentric left ventricular hypertrophy of obesity. Am J Cardiol 1991;68:95–98.PubMedGoogle Scholar
  78. 78.
    Poirier P, Bogaty P, Garneau C, et al. Diastolic dysfunction in type 2 diabetes men without hypertension or coronary artery disease: importance of the Valsalva maneuver in screening patients. Diabetes Care 2001;24:5–10.PubMedGoogle Scholar
  79. 79.
    Dumesnil JG, Gaudreault G, Honos GN, et al. Use of Valsalva maneuver to unmask left ventricular diastolic function abnormalities by Doppler echocardiography in patients with coronary artery disease or systemic hypertension. Am J Cardiol 1991;68:515–519.PubMedGoogle Scholar
  80. 80.
    Drenick EJ, Fisler JS. Sudden cardiac arrest in morbidly obese surgical patients unexplained after autopsy. Am J Surg 1988;155:720–726.PubMedGoogle Scholar
  81. 81.
    Messerli FH, Sundgaard-Riise K, Reisin ED, et al. Dimorphic cardiac adaptation to obesity and arterial hypertension. Ann Intern Med 1983;99:757–761.PubMedGoogle Scholar
  82. 82.
    Iacobellis G, Ribaudo MC, Leto G, et al. Influence of excess fat on cardiac morphology and function: study in uncomplicated obesity. Obes Res 2002;10:767–773.PubMedGoogle Scholar
  83. 83.
    Morabito D, Vallotton MB, Lang U. Obesity is associated with impaired ventricular protein kinase C-MAP kinase signaling and altered ANP mRNA expression in the heart of adult Zucker rats. J Invest Med 2001;49:310–318.Google Scholar
  84. 84.
    van de WG, Zaninetti D, Lang U, et al. Identification of a major defect in insulin-resistant tissues of genetically obese (fa/fa) rats. Impaired protein kinase C. Diabetes 1987;36:310–314.PubMedGoogle Scholar
  85. 85.
    Kylin E. Studien über das Hypertonie-Hyperglykämie-Hyperurikämiessyndrom. Zentralbl Innere Med 2005;7:105–127.Google Scholar
  86. 86.
    Vague J. La différenciation sexuelle. Facteur déterminant des formes d’obésité. Presse Med 2005;55:330–331.Google Scholar
  87. 87.
    Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415–1428.PubMedGoogle Scholar
  88. 88.
    Grundy SM, Hansen B, Smith SC Jr, et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/ American Diabetes Association conference on scientific issues related to management. Circulation 2004;109:551–556.PubMedGoogle Scholar
  89. 89.
    Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782–787.PubMedGoogle Scholar
  90. 90.
    Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595–1607.PubMedGoogle Scholar
  91. 91.
    DeFronzo RA. Insulin resistance, hyperinsulinemia, and coronary artery disease: a complex metabolic web [Review] [123 refs]. J Cardiovasc Pharmacol 1992;20(suppl 11):S1–16.PubMedGoogle Scholar
  92. 92.
    Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989;149:1514–1520.PubMedGoogle Scholar
  93. 93.
    Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683–689.PubMedGoogle Scholar
  94. 94.
    Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709–2716.PubMedGoogle Scholar
  95. 95.
    Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000;102:179–184.PubMedGoogle Scholar
  96. 96.
    Tanko LB, Bagger YZ, Qin G, et al. Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation 2005;111:1883–1890.PubMedGoogle Scholar
  97. 97.
    Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539–553.PubMedGoogle Scholar
  98. 98.
    Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.Google Scholar
  99. 99.
    Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442–443.PubMedGoogle Scholar
  100. 100.
    Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003;9:237–252.PubMedGoogle Scholar
  101. 101.
    Ruderman N, Chisholm D, Pi-Sunyer X, et al. The metabolically obese, normal-weight individual revisited. Diabetes 1998;47:699–713.PubMedGoogle Scholar
  102. 102.
    Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004;33:351–375, table.PubMedGoogle Scholar
  103. 103.
    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356–359.PubMedGoogle Scholar
  104. 104.
    Azizi F, Salehi P, Etemadi A, et al. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res Clin Pract 2003;61:29–37.PubMedGoogle Scholar
  105. 105.
    Regional Office for the Western Pacific of the World Health Organization IAftSoOatIOTF. The Asia-Pacific perspective: redefining obesity and its treatment., 2005.Google Scholar
  106. 106.
    Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002;346:802–810.PubMedGoogle Scholar
  107. 107.
    Wei JN, Sung FC, Lin CC, et al. National surveillance for type 2 diabetes mellitus in Taiwanese children. JAMA 2003;290: 1345–1350.PubMedGoogle Scholar
  108. 108.
    Sung RY, Tong PC, Yu CW, et al. High prevalence of insulin resistance and metabolic syndrome in overweight/obese preadolescent Hong Kong Chinese children aged 9–12 years. Diabetes Care 2003;26:250–251.PubMedGoogle Scholar
  109. 109.
    Alberti G, Zimmet P, Shaw J, et al. Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care 2004;27:1798–1811.PubMedGoogle Scholar
  110. 110.
    Cook S, Weitzman M, Auinger P, et al. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994. Arch Pediatr Adolesc Med 2003;157:821–827.PubMedGoogle Scholar
  111. 111.
    Whitaker RC, Wright JA, Pepe MS, et al. Predicting obesity in young adulthood from childhood and parental obesity. N Engl J Med 1997;337:869–873.PubMedGoogle Scholar
  112. 112.
    Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004;93:136–141.PubMedGoogle Scholar
  113. 113.
    Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110:1245–1250.PubMedGoogle Scholar
  114. 114.
    Hu G, Qiao Q, Tuomilehto J, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004;164:1066–1076.PubMedGoogle Scholar
  115. 115.
    Bonora E, Targher G, Formentini G, et al. The Metabolic Syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 2004;21:52–58.PubMedGoogle Scholar
  116. 116.
    Ninomiya JK, L’Italien G, Criqui MH, et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. Circulation 2004;109:42–46.PubMedGoogle Scholar
  117. 117.
    Eckel RH. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 1989;320:1060–1068.PubMedGoogle Scholar
  118. 118.
    Poirier P, Eckel RH. Adipose tissue metabolism and obesity. In: Claude Bouchard, ed. Physical Activity and Obesity. Champaign: Human Kinetics, 2000:181–200.Google Scholar
  119. 119.
    Lee S, Janssen I, Ross R. Interindividual variation in abdominal subcutaneous and visceral adipose tissue: influence of measurement site. J Appl Physiol 2004;97:948–954.PubMedGoogle Scholar
  120. 120.
    Pouliot MC, Despres JP, Moorjani S, et al. Computed tomography-measured trunk fat and plasma lipoprotein levels in nonobese women. Metabolism 1989;38:1244–1250.PubMedGoogle Scholar
  121. 121.
    Pouliot MC, Despres JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73:460–468.PubMedGoogle Scholar
  122. 122.
    Aubert H, Frere C, Aillaud MF, et al. Weak and non-independent association between plasma TAFIantigen levels and the insulin resistance syndrome. J Thromb Haemost 2003;1:791–797.PubMedGoogle Scholar
  123. 123.
    Bajaj M, Banerji MA. Type 2 diabetes in South Asians: a pathophysiologic focus on the Asian-Indian epidemic. Curr Diab Rep 2004;4:213–218.PubMedGoogle Scholar
  124. 124.
    Tanaka S, Horimai C, Katsukawa F. Ethnic differences in abdominal visceral fat accumulation between Japanese, African-Americans, and Caucasians: a meta-analysis. Acta Diabetol 2003;40(suppl 1):S302–S304.PubMedGoogle Scholar
  125. 125.
    Guo Z, Hensrud DD, Johnson CM, et al. Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes 1999;48:1586–1592.PubMedGoogle Scholar
  126. 126.
    Lewis GF, Uffelman KD, Szeto LW, et al. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 1995;95:158–166.PubMedGoogle Scholar
  127. 127.
    Lewis GF, Steiner G. Acute effects of insulin in the control of VLDL production in humans. Implications for the insulinresistant state. Diabetes Care 1996;19:390–393.PubMedGoogle Scholar
  128. 128.
    Taghibiglou C, Rashid-Kolvear F, Van Iderstine SC, et al. Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance. J Biol Chem 2002;277:793–803.PubMedGoogle Scholar
  129. 129.
    Eckel RH, Yost TJ, Jensen DR. Alterations in lipoprotein lipase in insulin resistance. Int J Obes Relat Metab Disord 1995;19(suppl 1):S16–S21.PubMedGoogle Scholar
  130. 130.
    Poirier P, Despres JP. Waist circumference, visceral obesity, and cardiovascular risk. J Cardiopulm Rehabil 2003;23:161–169.PubMedGoogle Scholar
  131. 131.
    Murakami T, Michelagnoli S, Longhi R, et al. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler Thromb Vasc Biol 1995;15:1819–1828.PubMedGoogle Scholar
  132. 132.
    Brinton EA, Eisenberg S, Breslow JL. Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest 1991;87:536–544.PubMedGoogle Scholar
  133. 133.
    de Graaf J, Hendriks JC, Demacker PN, et al. Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment. Arterioscler Thromb 1993;13:712–719.PubMedGoogle Scholar
  134. 134.
    Manzato E, Zambon S, Zambon A, et al. Levels and physicochemical properties of lipoprotein subclasses in moderate hypertriglyceridemia. Clin Chim Acta 1993;219:57–65.PubMedGoogle Scholar
  135. 135.
    Packard CJ. LDL subfractions and atherogenicity: an hypothesis from the University of Glasgow. Curr Med Res Opin 1996;13:379–390.PubMedGoogle Scholar
  136. 136.
    Krauss RM. Dense low density lipoproteins and coronary artery disease. Am J Cardiol 1995;75:53B–57B.PubMedGoogle Scholar
  137. 137.
    Zambon A, Hokanson JE, Brown BG, et al. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 1999;99:1959–1964.PubMedGoogle Scholar
  138. 138.
    Sacks FM, Campos H. Clinical review 163: Cardiovascular endocrinology: low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab 2003;88:4525–4532.PubMedGoogle Scholar
  139. 139.
    Hokanson JE. Hypertriglyceridemia and risk of coronary heart disease. Curr Cardiol Rep 2002;4:488–493.PubMedGoogle Scholar
  140. 140.
    Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002;23:201–229.PubMedGoogle Scholar
  141. 141.
    Ferrannini E. Insulin and blood pressure: connected on a circumference? Hypertension 2005;45:347–348.PubMedGoogle Scholar
  142. 142.
    Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:575–594, ix.PubMedGoogle Scholar
  143. 143.
    Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202–1219.PubMedGoogle Scholar
  144. 144.
    Facchini F, Chen YD, Hollenbeck CB, et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991;266:3008–3011.PubMedGoogle Scholar
  145. 145.
    Egan BM. Insulin resistance and the sympathetic nervous system. Curr Hypertens Rep 2003;5:247–254.PubMedGoogle Scholar
  146. 146.
    Rowley K, O’Dea K, Best JD. Association of albuminuria and the metabolic syndrome. Curr Diab Rep 2003;3:80–86.PubMedGoogle Scholar
  147. 147.
    Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003;24:278–301.PubMedGoogle Scholar
  148. 148.
    Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347–355.PubMedGoogle Scholar
  149. 149.
    Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796–1808.PubMedGoogle Scholar
  150. 150.
    Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821–1830.PubMedGoogle Scholar
  151. 151.
    Lamonte MJ, Durstine JL, Yanowitz FG, et al. Cardiorespiratory fitness and C-reactive protein among a tri-ethnic sample of women. Circulation 2002;106:403–406.PubMedGoogle Scholar
  152. 152.
    Chambers JC, Eda S, Bassett P, et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 2001;104:145–150.PubMedGoogle Scholar
  153. 153.
    Hunt KJ, Resendez RG, Williams K, et al. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004;110:1251–1257.PubMedGoogle Scholar
  154. 154.
    Wilson PW. Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view. Endocrinol Metab Clin North Am 2004;33:467–481, v.PubMedGoogle Scholar
  155. 155.
    Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of tenyear risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987–1003.PubMedGoogle Scholar
  156. 156.
    Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433–438.PubMedGoogle Scholar
  157. 157.
    Lamarche B, Tchernof A, Mauriege P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998;279:1955–1961.PubMedGoogle Scholar
  158. 158.
    Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study. Circulation 2002;105:310–315.PubMedGoogle Scholar
  159. 159.
    Van den Hoogen PC, Feskens EJ, Nagelkerke NJ, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med 2000;342:1–8.PubMedGoogle Scholar
  160. 160.
    Liu J, Hong Y, D’Agostino RB Sr, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 2004;291:2591–2599.PubMedGoogle Scholar
  161. 161.
    Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004;53:2087–2094.PubMedGoogle Scholar
  162. 162.
    Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004;110:2952–2967.PubMedGoogle Scholar
  163. 163.
    Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999;341:879–884.PubMedGoogle Scholar
  164. 164.
    Bell CG, Walley AJ, Froguel P. The genetics of human obesity. Nat Rev Genet 2005;6:221–234.PubMedGoogle Scholar
  165. 165.
    Coll AP, Farooqi IS, Challis BG, et al. Proopiomelanocortin and energy balance: insights from human and murine genetics. J Clin Endocrinol Metab 2004;89:2557–2562.PubMedGoogle Scholar
  166. 166.
    Snyder EE, Walts B, Perusse L, et al. The human obesity gene map: the 2003 update. Obes Res 2004;12:369–439.PubMedGoogle Scholar
  167. 167.
    Stunkard AJ, Foch TT, Hrubec Z. A twin study of human obesity. JAMA 1986;256:51–54.PubMedGoogle Scholar
  168. 168.
    Stunkard AJ, Sorensen TI, Hanis C, et al. An adoption study of human obesity. N Engl J Med 1986;314:193–198.PubMedGoogle Scholar
  169. 169.
    Vohl MC, Sladek R, Robitaille J, et al. A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men. Obes Res 2004;12:1217–1222.PubMedGoogle Scholar
  170. 170.
    Bouchard L, Drapeau V, Provencher V, et al. Neuromedin beta: a strong candidate gene linking eating behaviors and susceptibility to obesity. Am J Clin Nutr 2004;80:1478–1486.PubMedGoogle Scholar
  171. 171.
    Poirier P, Martin J, Marceau P, et al. Impact of bariatric surgery on cardiac structure, function and clinical manifestations in morbid obesity. Expert Rev Cardiovasc Ther 2004;2:193–201.PubMedGoogle Scholar
  172. 172.
    McGill HC. Fatty streaks in the coronary arteries and aorta. Lab Invest 1968;18:560–564.PubMedGoogle Scholar
  173. 173.
    Skalen K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002;417:750–754.PubMedGoogle Scholar
  174. 174.
    Joseph LJ, Ryan AS, Sorkin J, et al. Body fat distribution and flow-mediated endothelium-dependent vasodilation in older men. Int J Obes Relat Metab Disord 2002;26:663–669.PubMedGoogle Scholar
  175. 175.
    Bots ML, Hofman A, GR’Obbee DE. Increased common carotid intima-media thickness. Adaptive response or a reflection of atherosclerosis? Findings from the Rotterdam Study. Stroke 1997;28:2442–2447.PubMedGoogle Scholar
  176. 176.
    Spence JD. Ultrasound measurement of carotid plaque as a surrogate outcome for coronary artery disease. Am J Cardiol 2002;89:10B–15B.PubMedGoogle Scholar
  177. 177.
    Heiss G, Sharrett AR, Barnes R, et al. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 1991;134:250–256.PubMedGoogle Scholar
  178. 178.
    Ciccone M, Vettor R, Pannacciulli N, et al. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord 2001;25:805–810.PubMedGoogle Scholar
  179. 179.
    Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intimamedia thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997;96:1432–1437.PubMedGoogle Scholar
  180. 180.
    O’Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999;340:14–22.PubMedGoogle Scholar
  181. 181.
    Freedman DS, Dietz WH, Tang R, et al. The relation of obesity throughout life to carotid intima-media thickness in adulthood: the Bogalusa Heart Study. Int J Obes Relat Metab Disord 2004;28:159–166.PubMedGoogle Scholar
  182. 182.
    Bogaty P, Poirier P, Simard S, et al. Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina. Circulation 2001;103:3062–3068.PubMedGoogle Scholar
  183. 183.
    Bogaty P, Robitaille NM, Solymoss S, et al. Atherogenic, hemostatic, and other potential risk markers in subjects with previous isolated myocardial infarction compared with longstanding uncomplicated stable angina. Am Heart J 1998;136:884–893.PubMedGoogle Scholar
  184. 184.
    McGill HC Jr, McMahan CA, Herderick EE, et al. Origin of atherosclerosis in childhood and adolescence. Am J Clin Nutr 2000;72:1307S–1315S.PubMedGoogle Scholar
  185. 185.
    Berenson GS. Bogalusa Heart Study: a long-term community study of a rural biracial (black/white) population. Am J Med Sci 2001;322:267–274.PubMedGoogle Scholar
  186. 186.
    Enos WF, Holmes RH, Beyer J. Coronary disease among United States soldiers killed in action in Korea. JAMA 1953;152:1090–1093.Google Scholar
  187. 187.
    McGill HC Jr, McMahan CA, Malcom GT, et al. Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol 1995;15:431–440.PubMedGoogle Scholar
  188. 188.
    Zieske AW, Malcom GT, Strong JP. Natural history and risk factors of atherosclerosis in children and youth: the PDAY study. Pediatr Pathol Mol Med 2002;21:213–237.PubMedGoogle Scholar
  189. 189.
    McGill HC Jr, McMahan CA, Herderick EE, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002;105:2712–2718.PubMedGoogle Scholar
  190. 190.
    Kortelainen ML, Sarkioja T. Visceral fat and coronary pathology in male adolescents. Int J Obes Relat Metab Disord 2001;25:228–232.PubMedGoogle Scholar
  191. 191.
    Kannel WB. The Framingham Study: historical insight on the impact of cardiovascular risk factors in men versus women. J Gend Specif Med 2002;5:27–37.PubMedGoogle Scholar
  192. 192.
    Kortelainen ML. Myocardial infarction and coronary pathology in severely obese people examined at autopsy. Int J Obes Relat Metab Disord 2002;26:73–79.PubMedGoogle Scholar
  193. 193.
    Rabkin SW, Mathewson FA, Hsu PH. Relation of body weight to development of ischemic heart disease in a cohort of young North American men after a 26 year observation period: the Manitoba Study. Am J Cardiol 1977;39:452–458.PubMedGoogle Scholar
  194. 194.
    Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968–977.PubMedGoogle Scholar
  195. 195.
    Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990;322:882–889.PubMedGoogle Scholar
  196. 196.
    Dagenais GR, Yi Q, Mann JF, et al. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005;149:54–60.PubMedGoogle Scholar
  197. 197.
    Kragelund C, Hassager C, Hildebrandt P, et al. Impact of obesity on long-term prognosis following acute myocardial infarction. Int J Cardiol 2005;98:123–131.PubMedGoogle Scholar
  198. 198.
    Gal RA, Gunasekera J, Massardo T, et al. Long-term prognostic value of a normal dipyridamole thallium-201 perfusion scan. Clin Cardiol 1991;14:971–974.PubMedGoogle Scholar
  199. 199.
    Ferraro S, Perrone-Filardi P, Desiderio A, et al. Left ventricular systolic and diastolic function in severe obesity: a radionuclide study. Cardiology 1996;87:347–353.PubMedGoogle Scholar
  200. 200.
    Freedman N, Schechter D, Klein M, et al. SPECT attenuation artifacts in normal and overweight persons: insights from a retrospective comparison of Rb-82 positron emission tomography and TI-201 SPECT myocardial perfusion imaging. Clin Nucl Med 2000;25:1019–1023.PubMedGoogle Scholar
  201. 201.
    Prvulovich EM, Lonn AH, Bomanji JB, et al. Transmission scanning for attenuation correction of myocardial 201Tl images in obese patients. Nucl Med Commun 1997;18:207–218.PubMedGoogle Scholar
  202. 202.
    Barnden LR, Ong PL, Rowe CC. Simultaneous emission transmission tomography using technetium-99m for both emission and transmission. Eur J Nucl Med 1997;24:1390–1397.PubMedGoogle Scholar
  203. 203.
    McNulty PH, Ettinger SM, Field JM, et al. Cardiac catheterization in morbidly obese patients. Catheter Cardiovasc Interv 2002;56:174–177.PubMedGoogle Scholar
  204. 204.
    Madu EC. Transesophageal dobutamine stress echocardiography in the evaluation of myocardial ischemia in morbidly obese subjects. Chest 2000;117:657–661.PubMedGoogle Scholar
  205. 205.
    Barbeau GR, Arsenault F, Dugas L, et al. Evaluation of the ulnopalmar arterial arches with pulse oximetry and plethysmography: comparison with the Allen’s test in 1010 patients. Am Heart J 2004;147:489–493.PubMedGoogle Scholar
  206. 206.
    Eisenstein EL, Shaw LK, Nelson CL, et al. Obesity and longterm clinical and economic outcomes in coronary artery disease patients. Obes Res 2002;10:83–91.PubMedGoogle Scholar
  207. 207.
    Gruberg L, Weissman NJ, Waksman R, et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol 2002;39:578–584.PubMedGoogle Scholar
  208. 208.
    Lakka TA, Lakka HM, Salonen R, et al. Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men. Atherosclerosis 2001;154:497–504.PubMedGoogle Scholar
  209. 209.
    Otsuka Y, Miyazaki S, Okumura H, et al. Abnormal glucose tolerance, not small vessel diameter, is a determinant of longterm prognosis in patients treated with balloon coronary angioplasty. Eur Heart J 2000;21:1790–1796.PubMedGoogle Scholar
  210. 210.
    St Pierre J, Lemieux I, Vohl MC, et al. Contribution of abdominal obesity and hypertriglyceridemia to impaired fasting glucose and coronary artery disease. Am J Cardiol 2002;90:15–18.PubMedGoogle Scholar
  211. 211.
    Korpilahti K, Syvanne M, Engblom E, et al. Components of the insulin resistance syndrome are associated with progression of atherosclerosis in non-grafted arteries 5 years after coronary artery bypass surgery. Eur Heart J 1998;19:711–719.PubMedGoogle Scholar
  212. 212.
    Kowalska I, Prokop J, Bachorzewska-Gajewska H, et al. Disturbances of glucose metabolism in men referred for coronary arteriography. Postload glycemia as predictor for coronary atherosclerosis. Diabetes Care 2001;24:897–901.PubMedGoogle Scholar
  213. 213.
    Qiao Q, Pyorala K, Pyorala M, et al. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J 2002;23:1267.PubMedGoogle Scholar
  214. 214.
    Marik P, Varon J. The obese patient in the ICU. Chest 1998;113:492–498.PubMedGoogle Scholar
  215. 215.
    Ascione R, Angelini GD. Is obesity still a risk factor for patients undergoing coronary surgery? Ital Heart J 2003;4:824–828.PubMedGoogle Scholar
  216. 216.
    Rockx MA, Fox SA, Stitt LW, et al. Is obesity a predictor of mortality, morbidity and readmission after cardiac surgery? Can J Surg 2004;47:34–38.PubMedGoogle Scholar
  217. 217.
    Moulton MJ, Creswell LL, Mackey ME, et al. Obesity is not a risk factor for significant adverse outcomes after cardiac surgery. Circulation 1996;94:II87–II92.PubMedGoogle Scholar
  218. 218.
    Birkmeyer NJ, Charlesworth DC, Hernandez F, et al. Obesity and risk of adverse outcomes associated with coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. Circulation 1998;97:1689–1694.PubMedGoogle Scholar
  219. 219.
    Kuduvalli M, Grayson AD, Oo AY, et al. Risk of morbidity and in-hospital mortality in obese patients undergoing coronary artery bypass surgery. Eur J Cardiothorac Surg 2002;22:787–793.PubMedGoogle Scholar
  220. 220.
    Rose DK, Cohen MM, Wigglesworth DF, et al. Critical respiratory events in the postanesthesia care unit. Patient, surgical, and anesthetic factors. Anesthesiology 1994;81:410–418.PubMedGoogle Scholar
  221. 221.
    Heuschmann PU, Berger K, Misselwitz B, et al. Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group. Stroke 2003;34:1106–1113.PubMedGoogle Scholar
  222. 222.
    Abbott RD, Behrens GR, Sharp DS, et al. Body mass index and thromboembolic stroke in nonsmoking men in older middle age. The Honolulu Heart Program. Stroke 1994;25:2370–2376.PubMedGoogle Scholar
  223. 223.
    Rhoads GG, Kagan A. The relation of coronary disease, stroke, and mortality to weight in youth and in middle age. Lancet 1983;1:492–495.PubMedGoogle Scholar
  224. 224.
    Shinton R, Shipley M, Rose G. Overweight and stroke in the Whitehall study. J Epidemiol Community Health 1991;45:138–142.PubMedGoogle Scholar
  225. 225.
    Rexrode KM, Hennekens CH, Willett WC, et al. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA 1997;277:1539–1545.PubMedGoogle Scholar
  226. 226.
    Lapidus L, Bengtsson C, Larsson B, et al. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J (Clin Res Ed) 1984;289:1257–1261.Google Scholar
  227. 227.
    Folsom AR, Prineas RJ, Kaye SA, et al. Incidence of hypertension and stroke in relation to body fat distribution and other risk factors in older women. Stroke 1990;21:701–706.PubMedGoogle Scholar
  228. 228.
    Terry RB, Page WF, Haskell WL. Waist/hip ratio, body mass index and premature cardiovascular disease mortality in US Army veterans during a twenty-three year follow-up study. Int J Obes Relat Metab Disord 1992;16:417–423.PubMedGoogle Scholar
  229. 229.
    Walker SP, Rimm EB, Ascherio A, et al. Body size and fat distribution as predictors of stroke among US men. Am J Epidemiol 1996;144:1143–1150.PubMedGoogle Scholar
  230. 230.
    Pyorala M, Miettinen H, Laakso M, et al. Hyperinsulinemia and the risk of stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Stroke 1998;29:1860–1866.PubMedGoogle Scholar
  231. 231.
    Kurth T, Gaziano JM, Berger K, et al. Body mass index and the risk of stroke in men. Arch Intern Med 2002;162:2557–2562.PubMedGoogle Scholar
  232. 232.
    Suk SH, Sacco RL, Boden-Albala B, et al. Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study. Stroke 2003;34:1586–1592.PubMedGoogle Scholar
  233. 233.
    Lindenstrom E, Boysen G, Nyboe J. Risk factors for stroke in Copenhagen, Denmark. II. Life-style factors. Neuroepidemiology 1993;12:43–50.PubMedGoogle Scholar
  234. 234.
    DiPietro L, Ostfeld AM, Rosner GL. Adiposity and stroke among older adults of low socioeconomic status: the Chicago Stroke Study. Am J Public Health 1994;84:14–19.PubMedGoogle Scholar
  235. 235.
    Selmer R, Tverdal A. Body mass index and cardiovascular mortality at different levels of blood pressure: a prospective study of Norwegian men and women. J Epidemiol Community Health 1995;49:265–270.PubMedGoogle Scholar
  236. 236.
    Kurth T, Gaziano JM, Rexrode KM, et al. Prospective study of body mass index and risk of stroke in apparently healthy women. Circulation 2005;111:1992–1998.PubMedGoogle Scholar
  237. 237.
    Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001;32:2575–2579.PubMedGoogle Scholar
  238. 238.
    Sriram K, Benkovic SA, Miller DB, et al. Obesity exacerbates chemically induced neurodegeneration. Neuroscience 2002;115:1335–1346.PubMedGoogle Scholar
  239. 239.
    Nielsen PE, Janniche H. The accuracy of auscultatory measurement of arm blood pressure in very obese subjects. Acta Med Scand 1974;195:403–409.PubMedGoogle Scholar
  240. 240.
    King GE. Errors in clinical measurement of blood pressure in obesity. Clin Sci 1967;32:223–237.PubMedGoogle Scholar
  241. 241.
    Kirkendall WM, Feinleib M, Freis ED, et al. Recommendations for human blood pressure determination by sphygmomanometers. Subcommittee of the AHA Postgraduate Education Committee. Circulation 1980;62:1146A–1155A.PubMedGoogle Scholar
  242. 242.
    Johnson AL, Cornoni JC, Cassel JC, et al. Influence of race, sex and weight on blood pressure behavior in young adults. Am J Cardiol 1975;35:523–530.PubMedGoogle Scholar
  243. 243.
    Voors AW, Webber LS, Frerichs RR, et al. Body height and body mass as determinants of basal blood pressure in children—The Bogalusa Heart Study. Am J Epidemiol 1977;106:101–108.PubMedGoogle Scholar
  244. 244.
    Dustan HP. Mechanisms of hypertension associated with obesity. Ann Intern Med 1983;98:860–864.PubMedGoogle Scholar
  245. 245.
    Pan WH, Nanas S, Dyer A, et al. The role of weight in the positive association between age and blood pressure. Am J Epidemiol 1986;124:612–623.PubMedGoogle Scholar
  246. 246.
    Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989;149:1514–1520.PubMedGoogle Scholar
  247. 247.
    Gottdiener JS, Reda DJ, Materson BJ, et al. Importance of obesity, race and age to the cardiac structural and functional effects of hypertension. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. J Am Coll Cardiol 1994;24:1492–1498.PubMedGoogle Scholar
  248. 248.
    Bjorntorp P. Classification of obese patients and complications related to the distribution of surplus fat. Nutrition 1990;6:131–137.PubMedGoogle Scholar
  249. 249.
    Bjorntorp P. Obesity and adipose tissue distribution as risk factors for the development of disease. A review. Infusionstherapie 1990;17:24–27.PubMedGoogle Scholar
  250. 250.
    Poirier P, Lemieux I, Mauriege P, et al. Impact of waist circumference on the relationship between blood pressure and insulin: the Quebec Health Survey. Hypertension 2005;45:363–367.PubMedGoogle Scholar
  251. 251.
    Muller DC, Elahi D, Pratley RE, et al. An epidemiological test of the hyperinsulinemia-hypertension hypothesis. J Clin Endocrinol Metab 1993;76:544–548.PubMedGoogle Scholar
  252. 252.
    Reisin E. Weight reduction in the management of hypertension: epidemiologic and mechanistic evidence. Can J Physiol Pharmacol 1986;64:818–824.PubMedGoogle Scholar
  253. 253.
    Ferrannini E. The haemodynamics of obesity: a theoretical analysis. J Hypertens 1992;10:1417–1423.PubMedGoogle Scholar
  254. 254.
    Hansen BC. The metabolic syndrome X. Ann N Y Acad Sci 1999;892:1–24.PubMedGoogle Scholar
  255. 255.
    Saad MF, Lillioja S, Nyomba BL, et al. Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med 1991;324:733–739.PubMedGoogle Scholar
  256. 256.
    Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med 2003;163:427–436.PubMedGoogle Scholar
  257. 257.
    Landsberg L, Troisi R, Parker D, et al. Obesity, blood pressure, and the sympathetic nervous system. Ann Epidemiol 1991;1:295–303.PubMedGoogle Scholar
  258. 258.
    Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–1252.PubMedGoogle Scholar
  259. 259.
    Tsutsu N, Nunoi K, Kodama T, et al. Lack of association between blood pressure and insulin in patients with insulinoma. J Hypertens 1990;8:479–482.PubMedGoogle Scholar
  260. 260.
    Hall JE, Brands MW, Mizelle HL, et al. Chronic intrarenal hyperinsulinemia does not cause hypertension. Am J Physiol 1991;260:F663–F669.PubMedGoogle Scholar
  261. 261.
    Bastard JP, Jardel C, Delattre J, et al. Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation 1999;99:2221–2222.PubMedGoogle Scholar
  262. 262.
    Frohlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000;23:1835–1839.PubMedGoogle Scholar
  263. 263.
    de Simone G, Wachtell K, Palmieri V, et al. Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. Circulation 2005;111:1924–1931.PubMedGoogle Scholar
  264. 264.
    Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999;341:1097–1105.PubMedGoogle Scholar
  265. 265.
    He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001;161:996–1002.PubMedGoogle Scholar
  266. 266.
    Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305–313.PubMedGoogle Scholar
  267. 267.
    Chen YT, Vaccarino V, Williams CS, et al. Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med 1999;106:605–612.PubMedGoogle Scholar
  268. 268.
    Wilhelmsen L, Rosengren A, Eriksson H, et al. Heart failure in the general population of men-morbidity, risk factors and prognosis. J Intern Med 2001;249:253–261.PubMedGoogle Scholar
  269. 269.
    Horwich TB, Fonarow GC, Hamilton MA, et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 2001;38:789–795.PubMedGoogle Scholar
  270. 270.
    Alla F, Briancon S, Juilliere Y, et al. Differential clinical prognostic classifications in dilated and ischemic advanced heart failure: the EPICAL study. Am Heart J 2000;139:895–904.PubMedGoogle Scholar
  271. 271.
    Osman AF, Mehra MR, Lavie CJ, et al. The incremental prognostic importance of body fat adjusted peak oxygen consumption in chronic heart failure. J Am Coll Cardiol 2000;36:2126–2131.PubMedGoogle Scholar
  272. 272.
    Lissin LW, Gauri AJ, Froelicher VF, et al. The prognostic value of body mass index and standard exercise testing in male veterans with congestive heart failure. J Card Fail 2002;8:206–215.PubMedGoogle Scholar
  273. 273.
    Davos CH, Doehner W, Rauchhaus M, et al. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail 2003;9:29–35.PubMedGoogle Scholar
  274. 274.
    Lavie CJ, Osman AF, Milani RV, et al. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol 2003;91:891–894.PubMedGoogle Scholar
  275. 275.
    Mosterd A, Cost B, Hoes AW, et al. The prognosis of heart failure in the general population: The Rotterdam Study. Eur Heart J 2001;22:1318–1327.PubMedGoogle Scholar
  276. 276.
    Hunt SA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration with the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 2001;104:2996–3007.PubMedGoogle Scholar
  277. 277.
    Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527–1560.PubMedGoogle Scholar
  278. 278.
    Curtis JP, Selter JG, Wang Y, et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 2005;165:55–61.PubMedGoogle Scholar
  279. 279.
    Grady KL, White-Williams C, Naftel D, et al. Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: a multi-institutional study of preoperative weight-height indices. Cardiac Transplant Research Database (CTRD) Group. J Heart Lung Transplant 1999;18:750–763.PubMedGoogle Scholar
  280. 280.
    Leung RS, Bradley TD. Sleep apnea and cardiovascular disease. Am J Respir Crit Care Med 2001;164:2147–2165.PubMedGoogle Scholar
  281. 281.
    Poirier P, Alpert MA. Heart disease. In: Eckel RH, ed. Obesity: Mechanisms and Clinical Management. Philadelphia: Williams & Wilkins, 2003:181–201.Google Scholar
  282. 282.
    Mackenzie J. The study of the pulse, arterial, venous and hepatic, and movements of the heart. Edinburg: 1902.Google Scholar
  283. 283.
    Nelson WP, North RL. Splitting of the second heart sound in adults forty years and older. Am J Med Sci 1967;254:805–807.PubMedGoogle Scholar
  284. 284.
    Weyman AE, Davidoff R, Gardin J, et al. Echocardiographic evaluation of pulmonary artery pressure with clinical correlates in predominantly obese adults. J Am Soc Echocardiogr 2002;15:454–462.PubMedGoogle Scholar
  285. 285.
    Roberts WC, Roberts JD. The floating heart or the heart too fat to sink: analysis of 55 necropsy patients. Am J Cardiol 1983;52:1286–1289.PubMedGoogle Scholar
  286. 286.
    Balsaver AM, Morales AR, Whitehouse FW. Fat infiltration of myocardium as a cause of cardiac conduction defect. Am J Cardiol 1967;19:261–265.PubMedGoogle Scholar
  287. 287.
    Spain DM, Cathcart RT. Heart block caused by fat infiltration of the inter-ventricular septum (cor adiposum). Am Heart J 1946;32:659–664.Google Scholar
  288. 288.
    Dervan JP, Ilercil A, Kane PB, et al. Fatty infiltration: another restrictive cardiomyopathic pattern. Cathet Cardiovasc Diagn 1991;22:184–189.PubMedGoogle Scholar
  289. 289.
    De Scheerder I, Cuvelier C, Verhaaren R, et al. Restrictive cardiomyopathy caused by adipositas cordis. Eur Heart J 1987;8:661–663.PubMedGoogle Scholar
  290. 290.
    Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 2000;97:1784–1789.PubMedGoogle Scholar
  291. 291.
    Pringle TH, Scobie IN, Murray RG, et al. Prolongation of the QT interval during therapeutic starvation: a substrate for malignant arrhythmias. Int J Obes 1983;7:253–261.PubMedGoogle Scholar
  292. 292.
    Sandhofer F, Dienstl F, Bolzano K, et al. Severe cardiovascular complication associated with prolonged starvation. Br Med J 1973;1:462–463.PubMedGoogle Scholar
  293. 293.
    Garnett ES, Barnard DL, Ford J, et al. Gross fragmentation of cardiac myofibrils after therapeutic starvation for obesity. Lancet 1969;1:914–916.PubMedGoogle Scholar
  294. 294.
    Rasmussen LH, Andersen T. The relationship between QTc changes and nutrition during weight loss after gastroplasty. Acta Med Scand 1985;217:271–275.PubMedGoogle Scholar
  295. 295.
    Alpert MA, Terry BE, Hamm CR, et al. Effect of weight loss on the ECG of normotensive morbidly obese patients. Chest 2001;119:507–510.PubMedGoogle Scholar
  296. 296.
    Pidlich J, Pfeffel F, Zwiauer K, et al. The effect of weight reduction on the surface electrocardiogram: a prospective trial in obese children and adolescents. Int J Obes Relat Metab Disord 1997;21:1018–1023.PubMedGoogle Scholar
  297. 297.
    Eisenstein I, Edelstein J, Sarma R, et al. The electrocardiogram in obesity. J Electrocardiol 1982;15:115–118.PubMedGoogle Scholar
  298. 298.
    Sours HE, Frattali VP, Brand CD, et al. Sudden death associated with very low calorie weight reduction regimens. Am J Clin Nutr 1981;34:453–461.PubMedGoogle Scholar
  299. 299.
    Isner JM, Sours HE, Paris AL, et al. Sudden, unexpected death in avid dieters using the liquid-protein-modified-fast diet. Observations in 17 patients and the role of the prolonged QT interval. Circulation 1979;60:1401–1412.PubMedGoogle Scholar
  300. 300.
    Frank S, Colliver JA, Frank A. The electrocardiogram in obesity: statistical analysis of 1,029 patients. J Am Coll Cardiol 1986;7:295–299.PubMedGoogle Scholar
  301. 301.
    Peiris AN, Thakur RK, Sothmann MS, et al. Relationship of regional fat distribution and obesity to electrocardiographic parameters in healthy premenopausal women. South Med J 1991;84:961–965.PubMedGoogle Scholar
  302. 302.
    Alpert MA, Terry BE, Cohen MV, et al. The electrocardiogram in morbid obesity. Am J Cardiol 2000;85:908–910.PubMedGoogle Scholar
  303. 303.
    Nomura A, Zareba W, Moss AJ. Obesity does not influence electrocardiographic parameters in coronary patients. Am J Cardiol 2000;85:106–108, A9.PubMedGoogle Scholar
  304. 304.
    Starr JW, Wagner GS, Behar VS, et al. Vectorcardiographic criteria for the diagnosis of inferior myocardial infarction. Circulation 1974;49:829–836.PubMedGoogle Scholar
  305. 305.
    Benjamin EJ, Levy D. Why is left ventricular hypertrophy so predictive of morbidity and mortality? Am J Med Sci 1999;317:168–175.PubMedGoogle Scholar
  306. 306.
    Alpert MA, Alexander JK. The Heart and Lung in Obesity. Armonk, NY: Futura, 1998.Google Scholar
  307. 307.
    Nath A, Alpert MA, Terry BE, et al. Sensitivity and specificity of electrocardiographic criteria for left and right ventricular hypertrophy in morbid obesity. Am J Cardiol 1988;62:126–130.PubMedGoogle Scholar
  308. 308.
    Collis T, Devereux RB, Roman MJ, et al. Relations of stroke volume and cardiac output to body composition: the strong heart study. Circulation 2001;103:820–825.PubMedGoogle Scholar
  309. 309.
    Bella JN, Devereux RB, Roman MJ, et al. Relations of left ventricular mass to fat-free and adipose body mass: the strong heart study. The Strong Heart Study Investigators. Circulation 1998;98:2538–2544.PubMedGoogle Scholar
  310. 310.
    Casale PN, Devereux RB, Kligfield P, et al. Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol 1985;6:572–580.PubMedGoogle Scholar
  311. 311.
    Abergel E, Tase M, Menard J, et al. Influence of obesity on the diagnostic value of electrocardiographic criteria for detecting left ventricular hypertrophy. Am J Cardiol 1996;77:739–744.PubMedGoogle Scholar
  312. 312.
    Kannel WB, Plehn JF, Cupples LA. Cardiac failure and sudden death in the Framingham Study. Am Heart J 1988;115:869–875.PubMedGoogle Scholar
  313. 313.
    Brown DW, Giles WH, Greenlund KJ, et al. Impaired fasting glucose, diabetes mellitus, and cardiovascular disease risk factors are associated with prolonged QTc duration. Results from the Third National Health and Nutrition Examination Survey. J Cardiovasc Risk 2001;8:227–233.PubMedGoogle Scholar
  314. 314.
    el-Gamal A, Gallagher D, Nawras A, et al. Effects of obesity on QT, RR, and QTc intervals. Am J Cardiol 1995;75:956–959.PubMedGoogle Scholar
  315. 315.
    Mshui ME, Saikawa T, Ito K, et al. QT interval and QT dispersion before and after diet therapy in patients with simple obesity. Proc Soc Exp Biol Med 1999;220:133–138.PubMedGoogle Scholar
  316. 316.
    Fukushige T, Yoshinaga M, Shimago A, et al. Effect of age and overweight on the QT interval and the prevalence of long QT syndrome in children. Am J Cardiol 2002;89:395–398.PubMedGoogle Scholar
  317. 317.
    Corbi GM, Carbone S, Ziccardi P, et al. FFAs and QT intervals in obese women with visceral adiposity: effects of sustained weight loss over 1 year. J Clin Endocrinol Metab 2002;87:2080–2083.PubMedGoogle Scholar
  318. 318.
    Girola A, Enrini R, Garbetta F, et al. QT dispersion in uncomplicated human obesity. Obes Res 2001;9:71–77.PubMedGoogle Scholar
  319. 319.
    Esposito K, Nicoletti G, Marzano S, et al. Autonomic dysfunction associates with prolongation of QT intervals and blunted night BP in obese women with visceral obesity. J Endocrinol Invest 2002;25:RC32–RC35.PubMedGoogle Scholar
  320. 320.
    Signal-averaged electrocardiography. J Am Coll Cardiol 1996;27:238–249.Google Scholar
  321. 321.
    Lalani AP, Kanna B, John J, et al. Abnormal signal-averaged electrocardiogram (SAECG) in obesity. Obes Res 2000;8:20–28.PubMedGoogle Scholar
  322. 322.
    Marfella R, De Angelis L, Nappo F, et al. Elevated plasma fatty acid concentrations prolong cardiac repolarization in healthy subjects. Am J Clin Nutr 2001;73:27–30.PubMedGoogle Scholar
  323. 323.
    Abraham R, Riemersma RA, Wood D, et al. Adipose fatty acid composition and the risk of serious ventricular arrhythmias in acute myocardial infarction. Am J Cardiol 1989;63:269–272.PubMedGoogle Scholar
  324. 324.
    D’Amico M, Marfella R, Nappo F, et al. High glucose induces ventricular instability and increases vasomotor tone in rats. Diabetologia 2001;44:464–470.PubMedGoogle Scholar
  325. 325.
    Marfella R, Nappo F, De Angelis L, et al. The effect of acute hyperglycaemia on QTc duration in healthy man. Diabetologia 2000;43:571–575.PubMedGoogle Scholar
  326. 326.
    Schouten EG, Dekker JM, Meppelink P, et al. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation 1991;84:1516–1523.PubMedGoogle Scholar
  327. 327.
    Peterson HR, Rothschild M, Weinberg CR, et al. Body fat and the activity of the autonomic nervous system. N Engl J Med 1988;318:1077–1083.PubMedGoogle Scholar
  328. 328.
    Hirsch J, Leibel RL, Mackintosh R, et al. Heart rate variability as a measure of autonomic function during weight change in humans. Am J Physiol 1991;261:R1418–R1423.PubMedGoogle Scholar
  329. 329.
    Poirier P, Hernandez TL, Weil KM, et al. Impact of diet-induced weight loss on the cardiac autonomic nervous system in severe obesity. Obes Res 2003;11:1040–1047.PubMedGoogle Scholar
  330. 330.
    Kannel WB, Kannel C, Paffenbarger RS Jr, et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987;113:1489–1494.PubMedGoogle Scholar
  331. 331.
    Seccareccia F, Pannozzo F, Dima F, et al. Heart rate as a predictor of mortality: the MATISS project. Am J Public Health 2001;91:1258–1263.PubMedGoogle Scholar
  332. 332.
    La Rovere MT, Bigger JT Jr, Marcus FI, et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998;351:478–484.PubMedGoogle Scholar
  333. 333.
    Arcaro G, Zamboni M, Rossi L, et al. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. Int J Obes Relat Metab Disord 1999;23:936–942.PubMedGoogle Scholar
  334. 334.
    Lee KU. Oxidative stress markers in Korean subjects with insulin resistance syndrome. Diabetes Res Clin Pract 2001;54(suppl 2):S29–S33.PubMedGoogle Scholar
  335. 335.
    Keaney JF Jr, Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003;23:434–439.PubMedGoogle Scholar
  336. 336.
    Marceau P, Hould FS, Potvin M, et al. Biliopancreatic diversion (duodenal switch procedure). Eur J Gastroenterol Hepatol 1999;11:99–103.PubMedGoogle Scholar
  337. 337.
    Schotte DE, Stunkard AJ. The effects of weight reduction on blood pressure in 301 obese patients. Arch Intern Med 1990;150:1701–1704.PubMedGoogle Scholar
  338. 338.
    Novi RF, Porta M, Lamberto M, et al. Reductions of body weight and blood pressure in obese hypertensive patients treated by diet. A retrospective study. Panminerva Med 1989;31:13–15.PubMedGoogle Scholar
  339. 339.
    Staessen J, Fagard R, Amery A. The relationship between body weight and blood pressure. J Hum Hypertens 1988;2:207–217.PubMedGoogle Scholar
  340. 340.
    Pontiroli AE, Pizzocri P, Saibene A, et al. Left ventricular hypertrophy and QT interval in obesity and in hypertension: effects of weight loss and of normalisation of blood pressure. Int J Obes Relat Metab Disord 2004;28:1118–1123.PubMedGoogle Scholar
  341. 341.
    Sjostrom CD, Peltonen M, Wedel H, et al. Differentiated longterm effects of intentional weight loss on diabetes and hypertension. Hypertension 2000;36:20–25.PubMedGoogle Scholar
  342. 342.
    Tsai AW, Cushman M, Rosamond WD, et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002;162:1182–1189.PubMedGoogle Scholar
  343. 343.
    Hansson PO, Eriksson H, Welin L, et al. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: “the study of men born in 1913”. Arch Intern Med 1999;159:1886–1890PubMedGoogle Scholar
  344. 344.
    Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997;277:642–645.PubMedGoogle Scholar
  345. 345.
    Blaszyk H, Wollan PC, Witkiewicz AK, et al. Death from pulmonary thromboembolism in severe obesity: lack of association with established genetic and clinical risk factors. Virchows Arch 1999;434:529–532.PubMedGoogle Scholar
  346. 346.
    Blaszyk H, Bjornsson J. Factor V Leiden and morbid obesity in fatal postoperative pulmonary embolism. Arch Surg 2000;135:1410–1413.PubMedGoogle Scholar
  347. 347.
    Kessler R, Chaouat A, Weitzenblum E, et al. Pulmonary hypertension in the obstructive sleep apnoea syndrome: prevalence, causes and therapeutic consequences. Eur Respir J 1996;9:787–794.PubMedGoogle Scholar
  348. 348.
    Laaban JP, Cassuto D, Orvoen-Frija E, et al. Cardiorespiratory consequences of sleep apnoea syndrome in patients with massive obesity. Eur Respir J 1998;11:20–27.PubMedGoogle Scholar
  349. 349.
    Marquis K, Maltais F, Duguay V, et al. The metabolic syndrome in chronic obstructive pulmonary disease patients. J Cardiopulm Rehabil 2005;25:226–232.PubMedGoogle Scholar
  350. 350.
    Amad KH, Brennan JC, Alexander JK. The cardiac pathology of chronic exogenous obesity. Circulation 1965;32:740–745.PubMedGoogle Scholar
  351. 351.
    James TN, Frame B, Coates EO. De subitaneis mortibus. 3. Pickwickian syndrome. Circulation 1973;48:1311–1320.PubMedGoogle Scholar
  352. 352.
    Sugerman HJ, Baron PL, Fairman RP, et al. Hemodynamic dysfunction in obesity hypoventilation syndrome and the effects of treatment with surgically induced weight loss. Ann Surg 1988;207:604–613.PubMedGoogle Scholar
  353. 353.
    Strollo PJJ, Rogers RM. Obstructive sleep apnea. N Engl J Med 1996;334:99–104.PubMedGoogle Scholar
  354. 354.
    Vgontzas AN, Tan TL, Bixler EO, et al. Sleep apnea and sleep disruption in obese patients. Arch Intern Med 1994;154:1705–1711.PubMedGoogle Scholar
  355. 355.
    Bearpark H, Elliott L, Grunstein R, et al. Snoring and sleep apnea. A population study in Australian men. Am J Respir Crit Care Med 1995;151:1459–1465.PubMedGoogle Scholar
  356. 356.
    Young T, Palta M, Dempsey J, et al. The occurrence of sleepdisordered breathing among middle-aged adults. N Engl J Med 1993;328:1230–1235.PubMedGoogle Scholar
  357. 357.
    Narkiewicz K, van de Borne PJ, Cooley RL, et al. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998;98:772–776.PubMedGoogle Scholar
  358. 358.
    Viner S, Szalai JP, Hoffstein V. Are history and physical examination a good screening test for sleep apnea? Ann Intern Med 1991;115:356–359.PubMedGoogle Scholar
  359. 359.
    Nieto FJ, Young TB, Lind BK, et al. Association of sleepdisordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000;283:1829–1836.PubMedGoogle Scholar
  360. 360.
    Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002;105:2462–2464.PubMedGoogle Scholar
  361. 361.
    Phillipson EA. Sleep apnea—a major public health problem. N Engl J Med 1993;328:1271–1273.PubMedGoogle Scholar
  362. 362.
    Partinen M, Jamieson A, Guilleminault C. Long-term outcome for obstructive sleep apnea syndrome patients. Mortality. Chest 1988;94:1200–1204.PubMedGoogle Scholar
  363. 363.
    Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683–2693.PubMedGoogle Scholar
  364. 364.
    Backman L, Freyschuss U, Hallberg D, et al. Cardiovascular function in extreme obesity. Acta Med Scand 1973;193:437–446.PubMedGoogle Scholar
  365. 365.
    MacMahon SW, Wilcken DE, Macdonald GJ. The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensive patients. N Engl J Med 1986;314:334–339.PubMedGoogle Scholar
  366. 366.
    Himeno E, Nishino K, Nakashima Y, et al. Weight reduction regresses left ventricular mass regardless of blood pressure level in obese subjects. Am Heart J 1996;131:313–319.PubMedGoogle Scholar
  367. 367.
    Tuck ML, Sowers J, Dornfeld L, et al. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981;304:930–933.PubMedGoogle Scholar
  368. 368.
    Sasson Z, Rasooly Y, Bhesania T, et al. Insulin resistance is an important determinant of left ventricular mass in the obese. Circulation 1993;88:1431–1436.PubMedGoogle Scholar
  369. 369.
    Harp JB, Henry SA, DiGirolamo M. Dietary weight loss decreases serum angiotensin-converting enzyme activity in obese adults. Obes Res 2002;10:985–990.PubMedGoogle Scholar
  370. 370.
    Lantigua RA, Amatruda JM, Biddle TL, et al. Cardiac arrhythmias associated with a liquid protein diet for the treatment of obesity. N Engl J Med 1980;303:735–738.PubMedGoogle Scholar
  371. 371.
    Singh BN, Gaarder TD, Kanegae T, et al. Liquid protein diets and torsade de pointes. JAMA 1978;240:115–119.PubMedGoogle Scholar
  372. 372.
    From the Centers for Disease Control and Prevention. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations. JAMA 1997;278:1729–1731.Google Scholar
  373. 373.
    Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995;92:790–795.PubMedGoogle Scholar
  374. 374.
    Redfield MM, Nicholson WJ, Edwards WD, et al. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992;117:50–52.PubMedGoogle Scholar
  375. 375.
    Ryan DH, Bray GA, Helmcke F, et al. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes Res 1999;7:313–322.PubMedGoogle Scholar
  376. 376.
    Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581–588.PubMedGoogle Scholar
  377. 377.
    Weissman NJ, Tighe JFJ, Gottdiener JS, et al. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med 1998;339:725–732.PubMedGoogle Scholar
  378. 378.
    Khan MA, Herzog CA, St, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998;339:713–718.PubMedGoogle Scholar
  379. 379.
    Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;335:609–616.PubMedGoogle Scholar
  380. 380.
    Jick H, Vasilakis C, Weinrauch LA, et al. A population-based study of appetite-suppressant drugs and the risk of cardiacvalve regurgitation. N Engl J Med 1998;339:719–724.PubMedGoogle Scholar
  381. 381.
    Weissman NJ, Panza JA, Tighe JF, et al. Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;134:267–273.PubMedGoogle Scholar
  382. 382.
    Mast ST, Jollis JG, Ryan T, et al. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med 2001;134:261–266.PubMedGoogle Scholar
  383. 383.
    Cannistra LB, Cannistra AJ. Regression of multivalvular regurgitation after the cessation of fenfluramine and phentermine treatment. N Engl J Med 1998;339:771.PubMedGoogle Scholar
  384. 384.
    Gardin JM, Schumacher D, Constantine G, et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000;283:1703–1709.PubMedGoogle Scholar
  385. 385.
    Gardin JM, Weissman NJ, Leung C, et al. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. JAMA 2001;286:2011–2014.PubMedGoogle Scholar
  386. 386.
    Palmieri V, Arnett DK, Roman MJ, et al. Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study. Am J Med 2002;112:710–715.PubMedGoogle Scholar
  387. 387.
    Davidoff R, McTiernan A, Constantine G, et al. Echocardiographic examination of women previously treated with fenfluramine: long-term follow-up of a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2001;161:1429–1436.PubMedGoogle Scholar
  388. 388.
    Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebocontrolled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167–172.PubMedGoogle Scholar
  389. 389.
    James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356:2119–2125.PubMedGoogle Scholar
  390. 390.
    McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998;56:1093–1124.PubMedGoogle Scholar
  391. 391.
    Bach DS, Rissanen AM, Mendel CM, et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res 1999;7:363–369.PubMedGoogle Scholar
  392. 392.
    Zannad F, Gille B, Grentzinger A, et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 2002;144:508–515.PubMedGoogle Scholar
  393. 393.
    Atkinson RL. Use of drugs in the treatment of obesity. Annu Rev Nutr 1997;17:383–403.PubMedGoogle Scholar
  394. 394.
    Wang F, Schultz AB, Musich S, et al. The relationship between National Heart, Lung, and Blood Institute Weight Guidelines and concurrent medical costs in a manufacturing population. Am J Health Promot 2003;17:183–189.PubMedGoogle Scholar
  395. 395.
    Cornier MA, Tate CW, Grunwald GK, et al. Relationship between waist circumference, body mass index, and medical care costs. Obes Res 2002;10:1167–1172.PubMedGoogle Scholar
  396. 396.
    Narbro K, Agren G, Jonsson E, et al. Pharmaceutical costs in obese individuals: comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: the SOS intervention study. Arch Intern Med 2002;162:2061–2069.PubMedGoogle Scholar
  397. 397.
    Agren G, Narbro K, Naslund I, et al. Long-term effects of weight loss on pharmaceutical costs in obese subjects. A report from the SOS intervention study. Int J Obes Relat Metab Disord 2002;26:184–192.PubMedGoogle Scholar
  398. 398.
    Sampalis JS, Liberman M, Auger S, et al. The impact of weight reduction surgery on health-care costs in morbidly obese patients. Obes Surg 2004;14:939–947.PubMedGoogle Scholar
  399. 399.
    Mitchell BM, Gutin B, Kapuku G, et al. Left ventricular structure and function in obese adolescents: relations to cardiovascular fitness, percent body fat, and visceral adiposity, and effects of physical training. Pediatrics 2002;109:E73.PubMedGoogle Scholar
  400. 400.
    Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002;347:1483–1492.PubMedGoogle Scholar
  401. 401.
    Lee CD, Blair SN, Jackson AS. Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men. Am J Clin Nutr 1999;69:373–380.PubMedGoogle Scholar
  402. 402.
    Gregg EW, Gerzoff RB, Thompson TJ, et al. Intentional weight loss and death in overweight and obese u.s. Adults 35 years of age and older. Ann Intern Med 2003;138:383–389.PubMedGoogle Scholar
  403. 403.
    Williamson DF, Pamuk E, Thun M, et al. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40–64 years. Am J Epidemiol 1995;141:1128–1141.PubMedGoogle Scholar
  404. 404.
    Williamson DF, Thompson TJ, Thun M, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000;23:1499–1504.PubMedGoogle Scholar
  405. 405.
    Gregg EW, Cheng YJ, Cadwell BL, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 2005;293:1868–1874.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2007

Authors and Affiliations

  • Paul Poirier
    • 1
  • Robert H. Eckel
    • 2
  1. 1.Department of CardiologyQuebec Heart Institute/Laval University Faculty of PharmacySte-FoyCanada
  2. 2.Division of Endocrinology, Metabolism and DiabetesUniversity of Colorado at Denver and Health Sciences CenterAuroraUSA

Personalised recommendations